<DOC>
	<DOCNO>NCT01282619</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy Huperzine A sustain release tablet patient mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Study Huperzine A Sustained-Release Tablets Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>The primary aim multicenter , randomize , double-blind , double-dummy , placebo- active-controlled therapeutic trial determine whether treatment huperzine A sustained-release tablet improve cognitive function individual AD . A total 390 participant randomly assign three group equal size . This allow comparison huperzine A sustained-release tablet 400µg day , huperzine A tablet 200µg twice day , placebo . The study divide 2 period : 1 . A two-week placebo run-in period 2 . A 6-month double blind treatment period , consist three month titration three month fix dose treatment .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huperzine A</mesh_term>
	<criteria>1 . Male/female patient age 50 85 2 . Clinical diagnosis mild moderate probable AD base DSMIV NINCDSADRDA criteria 3 . Middle school : 11 ≤MMSE ≤ 24 , elementary school : 8 ≤ MMSE ≤ 20 , illiteracy : 5 ≤ MMSE ≤ 16 ; 4 . CT MRI scan exclude another structural brain disease ; 5 . Hachinski Ischemic Score &lt; 4 6 . Hamilton Depression Scale ≤10 7 . Informed consent patient ( legal representative ) caregiver agree take part study . 1 . Proven clinically suspect type dementia vascular dementia , mechanic chemical cause dementia , vitamin B12 deficiency , hypothyroidism etc . 2 . Epileptic Patient 3 . Severe liver renal disease 4 . Resting pulse less 50 5 . Mechanical intestinal obstruction patient 6 . History stroke 7 . History angina severe cardiac , vascular , lung , gastrointestinal hematopoietic system disease 8 . Cognitive damage cause alcohol substance abuse 9 . Disable participate cooperate protocol 10 . Use agent treatment dementia within 2 week randomization 11 . Use another investigational agent within 3 month screen 12 . Be sensitive Huperzine A ACHEIs .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>